Etiology of lung cancer: Evidence from epidemiologic studies-Reference-Cited by-同舟云学术

Etiology of lung cancer: Evidence from epidemiologic studies

Published:2022-12 Issue:4 Volume:2 Page:216-225
ISSN:2667-0054
Container-title:Journal of the National Cancer Center
language:en
Short-container-title:Journal of the National Cancer Center

Author:

Zou Kaiyong,Sun Peiyuan,Huang Huang^ORCID,Zhuo Haoran,Qie Ranran,Xie Yuting,Luo Jiajun^ORCID,Li Ni,Li Jiang,He Jie,Aschebrook-Kilfoy Briseis^ORCID,Zhang Yawei^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology,Cancer Research

Reference238 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Global patterns and trends in lung cancer incidence: a population-based study;Zhang;J Thorac Oncol,2021

3. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016

4. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades;Lu;Cancer Manag Res,2019

5. Histological subtypes of lung cancer in Chinese males from 2000 to 2012;Zou;Biomed Environ Sci,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers;BMC Medicine;2024-09-11

2. Role of SCAL1 in Modulating Oxidative Stress, Cancer Stemness, Apoptotic Resistance in Tumorigenic Differentiation of Cigarette Smoke-Exposed BEAS-2B Cells;2024-08-07

3. Role of 4-Thiazolidinone–Pyrazoline/Indoline Hybrids Les-4369 and Les-3467 in BJ and A549 Cell Lines;Cells;2024-06-08

4. Integrated endoscopic treatment of primitive unresectable tracheal tumor: the INTACT retrospective cohort study;Journal of Thoracic Disease;2024-05

5. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study);Frontiers in Immunology;2024-01-15